The role of vasodilators in the prevention and treatment of no-reflow following percutaneous coronary intervention
- PMID: 16606861
- PMCID: PMC1861163
- DOI: 10.1136/hrt.2006.088427
The role of vasodilators in the prevention and treatment of no-reflow following percutaneous coronary intervention
Abstract
The routine use of vasodilators in patients with acute coronary syndromes or other groups undergoing percutaneous coronary intervention (PCI) cannot be recommended at present. However, in the event of no-reflow occurring following PCI, intracoronary adenosine or verapamil should be administered.
Conflict of interest statement
Conflict of interest statement: There are no conflicts of interest to declare.
Comment on
-
Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes.Heart. 2006 Sep;92(9):1278-84. doi: 10.1136/hrt.2005.075077. Epub 2006 Jan 31. Heart. 2006. PMID: 16449518 Free PMC article. Clinical Trial.
References
-
- Piana R, Paik G, Moscucci M.et al Incidence and treatment of ‘no‐reflow' after percutaneous coronary intervention. Circulation 1994892514–2518. - PubMed
-
- Abbo K M, Dooris M, Glazier S.et al Features and outcome of no‐reflow after percutaneous coronary intervention. Am J Cardiol 199575778–782. - PubMed
-
- Eeckhout E, Kern M J. The coronary no‐reflow phenomenon: a review of mechanisms and therapies. Eur Heart J 200122729–739. - PubMed
-
- Herrmann J. Peri‐procedural myocardial injury: 2005 update. Eur Heart J 2005262493–2519. - PubMed
-
- Wilson R F, Laxson D D, Lesser J R.et al Intense microvascular constriction after angioplasty of acute thrombotic coronary arterial lesions. Lancet 1989i807–811. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous